Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
Gut and Liver
;
: 270-275, 2017.
Article
in English
| WPRIM
| ID: wpr-69992
ABSTRACT
BACKGROUND/AIMS:
Because of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and available treatment outcomes of patients with genotype 6 HCV in Korea.METHODS:
From 2004 to 2014, data were collected from Korean patients infected with genotype 6 HCV in eight hospitals.RESULTS:
Thirty-two patients had genotype 6 HCV. The median age was 44 years, and 6c was the most common subtype. The baseline median alanine transaminase level was 88 (21 to 1,019) IU/mL, and the HCV RNA level was 1,405,000 (96,500 to 28,844,529) IU/mL. Twenty-five patients were treated with peginterferon (PEG-IFN) and ribavirin. Three follow-up losses occurred. Additionally, 13 patients attained a sustained virologic response (SVR), seven patients relapsed, and two patients exhibited a null response. The SVR rates were 40% and 75% for the 24- and more than 48-week treatments, respectively, and five of the six patients who achieved a rapid virologic response (RVR) attained a SVR.CONCLUSIONS:
Korean patients infected with genotype 6 HCV are relatively young, and 6c is the most common subtype. When treated with PEG-IFN and ribavirin, the SVR rate was 52%. Similar to other genotypes, a longer duration of treatment and attainment of RVR are important for SVR.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Ribavirin
/
RNA
/
Follow-Up Studies
/
Treatment Outcome
/
Hepatitis C
/
Hepacivirus
/
Hepatitis C, Chronic
/
Alanine Transaminase
/
Genotype
/
Hepatitis
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Gut and Liver
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS